Pfizer grows investigational RSV vaccine programmes with acquisition of ReViral
Pzifer's acquisition of ReViral will include its portfolio of promising…
Pzifer's acquisition of ReViral will include its portfolio of promising therapeutic candidates, such as sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host cell.